Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03507790 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
A Phase 2 study of Mild to Moderate Alzheimer's Disease, sponsored by Cognition Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT03507790: Completed Phase 2 study of Mild to Moderate Alzheimer's Disease, sponsored by Cognition Therapeutics.
NCT03507790 is a Phase 2 study of Mild to Moderate Alzheimer's Disease that has completed, run by Cognition Therapeutics. The registered enrollment target is 153 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03507790, a Phase 2 study of Mild to Moderate Alzheimer's Disease, has completed, sponsored by Cognition Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).
Primary Outcome
Adverse events were captured from the start of study-related procedures at Visit 1 (including diagnostic assessments or signing of ICF) onward during the course of this study. Adverse events were coded using MedDRA Version 27.0.TEAEs are events that occurred or worsened on or after the first application of study drug. Participants are counted once for each system organ class (SOC) and once for each preferred term (PT).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CT1812
Study Locations (20)
Florida
- JEM Research Institute - Atlantis
- Charter Research - Lady Lake
- ClinCloud, LLC - Maitland
- Allied Biomedical Research Institute - Miami
- Compass Research LLC- Bioclinica Research - The Villages
- ClinCloud - Viera
Other
- Neuro Health Centrum ltd - Brno
- NeuropsychiatrieHK S.R.O - Hradec Králové
- A-Shine S.R.O - Pilsen
- Clintrial S.R.O - Prague
Victoria
- St Vincent's Hospital Sydney - Ivanhoe
- Alfred Health - Melbourne
- Melbourne Health - Parkville
Arizona
- 21st Century Neurology/ Xenoscience Inc. - Phoenix
- Imaging Endpoints - Scottsdale
Ohio
- The Ohio State University - Wexner - Columbus
- Neuro Behavirol Clinical Research C - North Canton
Connecticut
- Ki Health Partners, LLC dba New England Institute for Clinical Research - Stamford
North Carolina
- Alzheimer's Memory Center - Charlotte
Western Australia
- Australian Alzheimer's Research Foundation - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2018-10-10 |
| Est. Completion | 2024-05-29 |
| Phase | Phase 2 |
What the finished NCT03507790 record still lists
NCT03507790 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% higher).
The record links to 1 condition, with Mild to Moderate Alzheimer's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03507790 names 20 study sites across 8 states, led by Florida, Other, Victoria.
Frequently Asked Questions
What is clinical trial NCT03507790 about?
NCT03507790 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.". This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).
What is the current status of trial NCT03507790?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2018-10-10. Estimated completion is 2024-05-29.
What conditions does trial NCT03507790 study?
This clinical trial studies the following conditions: Mild to Moderate Alzheimer's Disease.
What interventions are being tested in trial NCT03507790?
The interventions under investigation include: Placebo (DRUG), CT1812 (DRUG).
Who is sponsoring clinical trial NCT03507790?
This trial is sponsored by Cognition Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03507790 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Florida, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild to Moderate Alzheimer's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03507790's enrollment target sits among peer trials
153 449th of 2000 higher than 1,549 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI